PDF(Pubmed)
Abstract：
BACKGROUND: Evidence-based recommendations for antiepileptic drug selection in cats beyond phenobarbital are limited, and additional studies are needed for cats where seizures remain inadequately controlled by administration of phenobarbital alone or for cats that cannot safely receive phenobarbital.
OBJECTIVE: To compare seizure frequency in cats before and after oral administration of zonisamide and describe adverse clinical or clinicopathologic effects in this cohort.
METHODS: Fifty-seven cats with a history of seizures.
METHODS: Multicenter, retrospective study. Median number of seizures per month and number of seizure days per month were compared before and after administration of zonisamide in all cats, a subgroup of cats with idiopathic epilepsy (IE), and a subgroup of cats receiving zonisamide as sole therapy. Clinical and clinicopathologic adverse effect data were also reported.
RESULTS: A median decrease of 1 (P = .001, 95% confidence interval (CI) [-1.0, -0.5]) seizure per month, and 1 (P = .003, 95% CI [-1.5, -0.2]) seizure days per month was found across all cats after oral administration of zonisamide. The subgroup with IE showed median decreases of 1 (P = .03, 95% CI [-2.0, -0.5]) and 2 (P = .01, 95% CI [-2.5, -1.0]), respectively. The most common clinical adverse effects were sedation (17%), ataxia (11%), hyporexia (17%), and emesis (5%). One cat developed mild nonregenerative anemia, 2 cats developed mild metabolic acidosis, and 6 cats showed mild increases in ALT and ALP.
CONCLUSIONS: Zonisamide was well tolerated and efficacious in controlling seizure activity in most cats.
OBJECTIVE: To compare seizure frequency in cats before and after oral administration of zonisamide and describe adverse clinical or clinicopathologic effects in this cohort.
METHODS: Fifty-seven cats with a history of seizures.
METHODS: Multicenter, retrospective study. Median number of seizures per month and number of seizure days per month were compared before and after administration of zonisamide in all cats, a subgroup of cats with idiopathic epilepsy (IE), and a subgroup of cats receiving zonisamide as sole therapy. Clinical and clinicopathologic adverse effect data were also reported.
RESULTS: A median decrease of 1 (P = .001, 95% confidence interval (CI) [-1.0, -0.5]) seizure per month, and 1 (P = .003, 95% CI [-1.5, -0.2]) seizure days per month was found across all cats after oral administration of zonisamide. The subgroup with IE showed median decreases of 1 (P = .03, 95% CI [-2.0, -0.5]) and 2 (P = .01, 95% CI [-2.5, -1.0]), respectively. The most common clinical adverse effects were sedation (17%), ataxia (11%), hyporexia (17%), and emesis (5%). One cat developed mild nonregenerative anemia, 2 cats developed mild metabolic acidosis, and 6 cats showed mild increases in ALT and ALP.
CONCLUSIONS: Zonisamide was well tolerated and efficacious in controlling seizure activity in most cats.
摘要：
背景：在苯巴比妥以外的猫中选择抗癫痫药物的循证建议有限，对于单独服用苯巴比妥不能充分控制癫痫发作的猫或不能安全接受苯巴比妥的猫，还需要进行其他研究。
目的：比较猫口服唑尼沙胺前后的癫痫发作频率，并描述该队列中的不良临床或临床病理影响。
方法：57只有癫痫发作史的猫。
方法：多中心，回顾性研究。比较所有猫服用唑尼沙胺前后每月癫痫发作的中位数和每月癫痫发作的天数，患有特发性癫痫（IE）的猫亚组，和一组接受唑尼沙胺作为唯一治疗的猫。还报告了临床和临床病理不良反应数据。
结果：每月癫痫发作中位数减少1（P=.001，95％置信区间（CI）[-1.0，-0.5]），在口服唑尼沙胺后，所有猫每月发现1天（P=0.003，95％CI[-1.5，-0.2]）癫痫发作。IE亚组显示中位数下降1（P=0.03，95％CI[-2.0，-0.5]）和2（P=0.01，95％CI[-2.5，-1.0]），分别。最常见的临床不良反应是镇静（17%），共济失调（11%），缺氧（17%），和呕吐（5%）。一只猫出现了轻度非再生性贫血,2只猫出现轻度代谢性酸中毒,6只猫显示ALT和ALP轻度增加。
结论：唑尼沙胺在控制大多数猫的癫痫发作中具有良好的耐受性和有效性。
目的：比较猫口服唑尼沙胺前后的癫痫发作频率，并描述该队列中的不良临床或临床病理影响。
方法：57只有癫痫发作史的猫。
方法：多中心，回顾性研究。比较所有猫服用唑尼沙胺前后每月癫痫发作的中位数和每月癫痫发作的天数，患有特发性癫痫（IE）的猫亚组，和一组接受唑尼沙胺作为唯一治疗的猫。还报告了临床和临床病理不良反应数据。
结果：每月癫痫发作中位数减少1（P=.001，95％置信区间（CI）[-1.0，-0.5]），在口服唑尼沙胺后，所有猫每月发现1天（P=0.003，95％CI[-1.5，-0.2]）癫痫发作。IE亚组显示中位数下降1（P=0.03，95％CI[-2.0，-0.5]）和2（P=0.01，95％CI[-2.5，-1.0]），分别。最常见的临床不良反应是镇静（17%），共济失调（11%），缺氧（17%），和呕吐（5%）。一只猫出现了轻度非再生性贫血,2只猫出现轻度代谢性酸中毒,6只猫显示ALT和ALP轻度增加。
结论：唑尼沙胺在控制大多数猫的癫痫发作中具有良好的耐受性和有效性。
